(Q38407182)

2 September 2017

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients (English)

1 reference

2 September 2017

1 reference

10

Jolanta Kupryjanczyk

1 reference

2 September 2017

5

Radoslaw Madry

1 reference

2 September 2017

8

Piotr Sobiczewski

1 reference

2 September 2017

Anna Felisiak-Golabek

1

1 reference

2 September 2017

Alina Rembiszewska

2

1 reference

2 September 2017

Iwona K Rzepecka

3

1 reference

2 September 2017

Lukasz Szafron

4

1 reference

2 September 2017

Magdalena Murawska

6

1 reference

2 September 2017

Tomasz Napiorkowski

7

1 reference

2 September 2017

Beata Osuch

9

1 reference

2 September 2017

Polish Ovarian Cancer Study Group (POCSG)

11

1 reference

2 September 2017

10 November 2011

1 reference

Journal of Ovarian Research

2 September 2017

1 reference

2 September 2017

4

1 reference

2 September 2017

1

1 reference

2 September 2017

20

1 reference

https://scigraph.springernature.com/pub.10.1186/1757-2215-4-20

2 September 2017

0 references

cites work

Survivin: a new target for anti-cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Survivin: a promising tumor biomarker

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Survivin, a cancer target with an emerging role in normal adult tissues

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Nuclear or cytoplasmic expression of survivin: what is the significance?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Chromosomal passengers: the four-dimensional regulation of mitotic events

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Nuclear survivin as a biomarker for non-small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Prognostic importance of survivin in breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Treatment of platinum-resistant ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Human survivin is a kinetochore-associated passenger protein

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Control of apoptosis and mitotic spindle checkpoint by survivin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Reporting results of cancer treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Salvage chemotherapy for epithelial ovarian carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Geographical variations in TP53 mutational spectrum in ovarian carcinomas.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Histopathological study of intraductal papillary mucinous tumor of the pancreas: special reference to the roles of Survivin and p53 in tumorigenesis of IPMT.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Nuclear export is essential for the tumor-promoting activity of survivin.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

An immunohistochemical study of p16(INK4a) expression in multistep thyroid tumourigenesis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Survivin is required for stable checkpoint activation in taxol-treated HeLa cells

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Suppression of centromere dynamics by Taxol in living osteosarcoma cells.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Survivin expression in human osteosarcoma is a marker for survival

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Regulation of microtubule stability and mitotic progression by survivin.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Transcriptional repression of the anti-apoptotic survivin gene by wild type p53.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223127

Carbonic anhydrase IX in oligodendroglial brain tumors

31 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1757-2215-4-20

Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer

21 January 2018

1 reference

12 December 2020

p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma

1 reference

12 December 2020

Possible mechanisms of paclitaxel-induced apoptosis

1 reference

12 December 2020

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

12 December 2020

Why TP53 status does not associate with clinical endpoints in ovarian cancer: facts and hypotheses

1 reference

12 December 2020

Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas

1 reference

12 December 2020

The prognostic significance of COX-2 and survivin expression in ovarian cancer

1 reference

12 December 2020

P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome

1 reference

12 December 2020

Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin

1 reference

12 December 2020

Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/1757-2215-4-20

1 reference

Dimensions Publication ID

2 September 2017

0 references

1 reference

2 September 2017

1 reference